Dyne Therapeutics, Inc. Net Fee Amt
Dyne Therapeutics, Inc. (DYN) had Net Fee Amt of $59.58 thousand as of 2026-07-22, per its 424B5 filed 2026-07-22.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-22
- 2026-07-22: Net Fee Amt $59.58K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-22 | $59.58K 424B5 · filed 2026-07-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |